BriaCell announces ongoing Phase 3 study enrolled over 75 patients

BriaCell (BCTX) Therapeutics announces that its ongoing Phase 3 clinical study has consented over 100 and has enrolled over 75 patients. BriaCell anticipates completing patient enrollment in late 2025 or early 2026, and may report top line data as early as H1-2026. BriaCell’s pivotal Phase 3 clinical study is evaluating BriaCell’s lead clinical candidate, Bria-IMT, plus immune check point inhibitor versus physician’s choice in advanced metastatic breast cancer. “We are pleased at the expanding patient enrollment in our Phase 3 study, and expect this to continue to grow,” stated Dr. William V. Williams, BriaCell’s President & CEO. “We believe our novel therapeutic approach has the potential to transform cancer care for metastatic breast cancer patients, and are determined to bring our novel immunotherapy to market to help these patients.”